ERBB2 and gastric cancer: Human epidermal growth factor receptor 2 (HER2) positive gastric cancer is an important subtype of gastric cancer, and immunotherapy targeting HER2 significantly improves the prognosis of patients with advanced gastric cancer, which has become the first-line standard of care for advanced gastric cancer (Qiu, 2016).